Status:
COMPLETED
The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study
Lead Sponsor:
National Taiwan University Hospital
Conditions:
H. Pylori Infection
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. Eradication of H. pylori infection could reduce the occurence or recurre...
Eligibility Criteria
Inclusion
- Patients are aged greater than 20 years who have persistent H. pylori infection after one treatment and are willing to receive second line rescue regimens, respectively, are considered eligible for enrollment.
Exclusion
- Children and teenagers aged less than 20 years,
- History of gastrectomy,
- Gastric malignancy, including adenocarcinoma and lymphoma,
- Previous allergic reaction to antibiotics (amoxicillin, clarithromycin, levofloxacin) and prompt pump inhibitors (esomeprazole),
- Contraindication to treatment drugs,
- Pregnant or lactating women, OR
- Severe concurrent disease.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
142 Patients enrolled
Trial Details
Trial ID
NCT00885417
Start Date
April 1 2009
End Date
December 1 2010
Last Update
April 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 10002